A federal judge trimmed a lawsuit that accuses Sanofi of cornering the market for an injectable form of a diabetes drug, ...

Mylan’s $465 million proposed settlement with CMS may not cover the amount of money it allegedly saved by improperly classifying EpiPens as a generic drug, according to research published Monday in ...

While Mylan agreed to settle its Medicaid rebate case with the federal government last week for $465 million, the drugmaker is not required to classify EpiPens as a branded drug under Medicaid’s ...

(Reuters) - Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more ...

In a congressional hearing last week, Mylan chief executive Heather Bresch did not give an accurate number concerning how much the company made from a two-pack of EpiPens, according to The Washington ...

As we have previously reported, Regeneron’s BPCIA case against Mylan regarding Mylan’s proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled to begin ...

(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy ...